• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Beauty Farm Medical And Health Industry (SEHK:2373) Stock Price Premium Hinges On Margin Gains

    Simply Wall St·08/29/2026 21:31:43
    Listen to the news

    Beauty Farm Medical and Health Industry stock has crept higher in recent weeks, yet the real drama is in the earnings tape. The company just reported another period of strong profit generation, with trailing twelve month earnings from continuing operations of ¥408.874m and a trailing net profit margin of 11.2%. That is a solid level for a high touch consumer services business, and it helps explain why the shares trade on a P/E of 10.8x.

    The question now is whether that earnings strength still justifies a premium price tag once investors work through the full set of numbers.

    Is Beauty Farm Medical and Health Industry now priced for perfection at 10.8x P/E, or does the earnings strength leave mispriced upside on the table? See how the current multiples line up in our valuation analysis for Beauty Farm Medical and Health Industry

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs H1 2025): ¥1,881.607m vs. ¥1,459.013m (up about 29.0%)
    • Net Income (Excl. Extra Items, H1 2026 vs H1 2025): ¥222.156m vs. ¥155.682m (up about 42.7%)
    • Basic EPS (H1 2026 vs H1 2025): ¥0.91 vs. ¥0.678027 (up about 34.3%)
    • Trailing Net Profit Margin (TTM, current vs. prior year): 11.2% vs. 9.3% (higher margin level on recent revenue)

    Tired of scrolling through dense tables and raw earnings figures on Beauty Farm Medical and Health Industry? Get a clear visual view of the company’s valuation and how the current P/E of 10.8x fits into the broader picture in the company report for Beauty Farm Medical and Health Industry.

    SEHK:2373 Trailing 12-Month Earnings & Revenue History as at Aug 2026
    SEHK:2373 Trailing 12-Month Earnings & Revenue History as at Aug 2026

    Beauty Farm earnings test the growth‑through‑upsell story

    The bullish story around Beauty Farm Medical and Health is that a premium city footprint plus upsell into medical aesthetic and subhealth services can steadily lift revenue and margins. The latest half year goes some way toward backing that up. Revenue reached ¥1,881.607m and net income excluding extra items came in at ¥222.156m. That supports a trailing net profit margin of 11.2%, above the prior 9.3%, which points to better economics rather than just higher volumes. Basic EPS of ¥0.91 for H1 2026 versus ¥0.678027 a year earlier is consistent with that margin lift. For a model built on higher value services and cross selling, this kind of earnings quality matters more than headline growth alone.

    Early signs also align with the consolidation angle. Management reports that recently acquired operations such as Naturade and Siyanli are contributing to per store revenue and margin improvement.

    Compare Beauty Farm Medical and Health Industry’s margin lift and cross selling story with what the street is pricing in, and see whether analysts think SEHK:2373 still has room for its premium to stretch in the consensus price target analysis for Beauty Farm Medical and Health Industry.

    Bear Case On Subhealth And Costs Meets Mixed Evidence

    Bears argue that Beauty Farm Medical and Health Industry is leaning on a subhealth and medical aesthetic boom that will be hard to sustain, while an experience heavy cost base caps margin gains. This set of numbers does not cleanly validate that concern, but it also does not put it to bed. Net income excluding extra items of ¥222.156m and a trailing net margin of 11.2% show the model still converts revenue into profit. However, investors do not yet see a clear breakout in profitability that would prove operating leverage from densification and acquisitions is firmly in place.

    The bear worry on acquisition complexity also remains open. Naturade and Siyanli are said to be helping per store metrics, but there is limited quantified disclosure on integration synergies. That makes it hard for you to rule out future M&A execution risk based on this print alone.

    After a string of acquisitions and a premium service mix, are integration and cost risks just the tip of the iceberg? Review our risk analysis for Beauty Farm Medical and Health Industry which shows 1 important warning sign.

    Take Control Of Your Next Move

    If Beauty Farm Medical and Health Industry’s recent margin profile and 10.8x P/E have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For longer term decisions, tap into the Community to see how other investors are thinking about the same risks and opportunities. By spotting potential catalysts and red flags early, you can keep your process ahead of the broader market.

    Seeking Alternatives Beyond Beauty Farm?

    Fresh ideas do not stay under the radar for long. The strongest stories can be flying before most investors notice. Scan these focused stock lists before the crowd and review them at an early stage.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.